Three different sodium oxybate formulations are available for the management of narcolepsy with/without cataplexy. While they are equally efficacious, there are differences such as dosing that require shared decision-making between patient and clinician to select the right formulation for each patient. Join Drs. Kushida and Thorpy as they share their approach to making the right treatment decision for each patient, one that includes ensuring patient preferences are considered.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Clete A. Kushida, MD, PhD
Professor of Psychiatry and Behavioral Sciences
Division Chief, Medical Director, Sleep Medicine
Stanford University School of Medicine
Dr. Kushida has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: XW Pharma
Research: Avadel Pharmaceuticals
Michael J. Thorpy, MD
Director, Sleep‐Wake Disorders Center
Montefiore Medical Center
Professor of Neurology
Albert Einstein College of Medicine, Bronx, NY
Dr. Thorpy has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting/Advisory Board: Alkermes, Avadel Pharmaceuticals, Axsome, Balance Therapeutics, Eisai Pharmaceuticals, Harmony Biosciences, LLC, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, NLS Pharmaceuticals, Suven Life Sciences Ltd., Takeda Pharmaceutical Co., Ltd, XW Pharma
- Jennifer Brutsche has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Barry Fiedel, PhD, has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Tim Person has nothing to disclose.
- Robert Schnieder has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Discuss the individual product attributes of the three sodium oxybate formulations
- Explain patient and clinician preference for sodium oxybate therapy based on product attributes
- Identify the criteria by which patients and clinicians can communicate about goals of treatment and negotiate decisions as to the therapeutic management approach
This activity is designed to meet the educational needs of the practicing Sleep Medicine Specialist, Psychiatrist, and Neurologist.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until January 29, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Avadel CNS Pharmaceuticals, LLC.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments0.50 credits
Scott Kahan, MD, MPH
Ken Fujioka, MD
Carol Wysham, MD
Anne Marie Morse, DO
Pediatric Narcolepsy: Addressing the Challenges in Its Recognition, Diagnosis, and Management0.25 credits
Michael J. Thorpy, MD
Anne Marie Morse, DO
The Treatment Pipeline for Primary Biliary Cholangitis: Sorting Out the PPARs1.00 program credit
Atoosa Rabiee, MD
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG